Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US

References

• GoASHylekEMPhillipsKAPrevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) studyJAMA2001285182370237511343485
   PubMed Web of Science ®Google Scholar
• GershBJTsangTSSewardJBThe changing epidemiology and natural history of nonvalvular atrial fibrillation: clinical implicationsTrans Am Clin Climatol Assoc2004115149159 discussion 159–16017060964
   PubMedGoogle Scholar
• KannelWBBenjaminEJCurrent perceptions of the epidemiology of atrial fibrillationCardiol Clin20092711324vii19111760
   PubMed Web of Science ®Google Scholar
• YouJJSingerDEHowardPAAntithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest20121412 Supple531Se575S22315271
   PubMed Web of Science ®Google Scholar
• FurieKLGoldsteinLBAlbersGWOral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke AssociationStroke201243123442345322858728
   PubMed Web of Science ®Google Scholar
  ErrataStroke2013443e20
   Google Scholar
  Stroke20124312e181
   Google Scholar
• JanuaryCTWannLSAlpertJS2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm SocietyJ Am Coll Cardiol20146421e1e7624685669
   PubMed Web of Science ®Google Scholar
• SarafKMorrisPGargPSheridanPStoreyRNon-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerationsPostgrad Med J201490106752052825085900
   PubMed Web of Science ®Google Scholar
• KatsnelsonMSaccoRLMoscucciMProgress for stroke prevention with atrial fibrillation: emergence of alternative oral anticoagulantsCirculation2012125121577158322451607
   PubMed Web of Science ®Google Scholar
• AndersonJLHeidenreichPABarnettPGACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice GuidelinesCirculation2014129222329234524677315
   PubMed Web of Science ®Google Scholar
• GageBFCardinalliABAlbersGWOwensDKCost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillationJAMA199527423183918457500532
   PubMed Web of Science ®Google Scholar
• SorensenSVDewildeSSingerDEGoldhaberSZMonzBUPlumbJMCost-effectiveness of warfarin: trial versus “real-world” stroke prevention in atrial fibrillationAm Heart J200915761064107319464418
   PubMed Web of Science ®Google Scholar
• JowettSBryanSMantJCost effectiveness of warfarin versus aspirin in patients older than 75 years with atrial fibrillationStroke20114261717172121512184
   PubMed Web of Science ®Google Scholar
• LimoneBLBakerWLKlugerJColemanCINovel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness modelsPLoS One201384e6218323626785
   PubMed Web of Science ®Google Scholar
• LimoneBLBakerWLMearnsESWhiteCMKlugerJColemanCICommon flaws exist in published cost-effectiveness models of pharmacologic stroke prevention in atrial fibrillationJ Clin Epidemiol201467101093110225018102
   PubMed Web of Science ®Google Scholar
• von SchéeleBFernandezMHogueSLKwongWJReview of economics and cost-effectiveness analyses of anticoagulant therapy for stroke prevention in atrial fibrillation in the USAnn Pharmacother201347567168523606551
   PubMed Web of Science ®Google Scholar
• KasmeridisCApostolakisSEhlersLRasmussenLHBorianiGLipGYCost effectiveness of treatments for stroke prevention in atrial fibrillation: focus on the novel oral anticoagulantsPharmacoeconomics2013311197198024085625
   PubMed Web of Science ®Google Scholar
• KansalARZhengYPokoraTSorensenSVCost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillationBest Pract Res Clin Haematol201326222523723953910
   PubMed Web of Science ®Google Scholar
• ManiHLindhoff-LastENew oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectivenessDrug Des Devel Ther20148789798
   PubMed Web of Science ®Google Scholar
• FerreiraJMircoASystematic review of cost-effectiveness analyses of novel oral anticoagulants for stroke prevention in atrial fibrillationRev Port Cardiol201534317919125727748
   PubMedGoogle Scholar
• Daiichi SankyoSavaysa (edoxaban) [package insert] Available from: http://dsi.com/prescribing-information-portlet/getPIContent?productName=Savaysa&inline=trueAccessed January 2, 2016
   Google Scholar
• GiuglianoRPRuffCTBraunwaldEEdoxaban versus warfarin in patients with atrial fibrillationN Engl J Med2013369222093210424251359
   PubMed Web of Science ®Google Scholar
• FernandezMMWangJYeXSystematic review and network meta-analysis of the relative efficacy and safety of edoxaban versus other nonvitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and CHADS2 score ≥2SAGE Open Med20153111
   Google Scholar
• MessoriAFaddaVMarateaDTrippoliSMarinaiCTesting the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillationInt J Clin Pharmacol Ther201553321121925295718
   PubMed Web of Science ®Google Scholar
• VerdecchiaPAngeliFBartoliniCSafety and efficacy of non- vitamin K oral anticoagulants in non-valvular atrial fibrillation: a Bayesian meta-analysis approachExpert Opin Drug Saf201514172025311731
   PubMed Web of Science ®Google Scholar
• SkjøthFLarsenTBRasmussenLHLipGYEfficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: an indirect comparison analysisThromb Haemost2014111598198824577485
   PubMed Web of Science ®Google Scholar
• FuWGuoHGuoJRelative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation by network meta-analysisJ Cardiovasc Med (Hagerstown)2014151287387925304034
   PubMed Web of Science ®Google Scholar
• AssiriAAl-MajzoubOKanaanAODonovanJLSilvaMMixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillationClin Ther2013357967984.e223870607
   PubMed Web of Science ®Google Scholar
• Biondi-ZoccaiGMalavasiVD’AscenzoFComparative effectiveness of novel oral anticoagulants for atrial fibrillation: evidence from pair-wise and warfarin-controlled network meta-analysesHSR Proc Intensive Care Cardiovasc Anesth201351405423734288
   PubMedGoogle Scholar
• Drugs.comUS pharmaceutical sales – Q4 20132014 Available from: http://www.drugs.com/stats/top100/salesAccessed January 2, 2016
   Google Scholar
• PatelMRMahaffeyKWGargJRivaroxaban versus warfarin in nonvalvular atrial fibrillationN Engl J Med20113651088389121830957
   PubMed Web of Science ®Google Scholar
• LipGYKongnakornTPhatakHCost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillationClin Ther2014362192210.e2024508420
   PubMed Web of Science ®Google Scholar
• DorianPKongnakornTPhatakHCost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillationEur Heart J201435281897190624513791
   PubMed Web of Science ®Google Scholar
• PistersRLaneDAMarinFCammAJLipGYStroke and thromboembolism in atrial fibrillationCirc J201276102289230423001018
   PubMed Web of Science ®Google Scholar
• WangYXieFKongMCLeeLHNgHJKoYCost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillationCardiovasc Drugs Ther201428657558525319314
   PubMed Web of Science ®Google Scholar
• No authors listedRisk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trialsArch Intern Med199415413144914578018000
   PubMed Web of Science ®Google Scholar
  ErratumArch Intern Med1994154192254
   Google Scholar
• National Institute for Health and Clinical Excellence (NICE)Apixaban (Eliquis^®) for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation. Single technology appraisal (STA) submitted by Bristol-Myers Squibb and Pfizer1782012 Available from: http://www.nice.org.uk/guidance/ta275/documents/stroke-and-systemic-embolism-prevention-nonvalvular-atrial-fibrillation-apixaban-bristolmyers-squibb-and-pfizer2Accessed January 2, 2016
   Google Scholar
• BosMJvan RijnMJWittemanJCHofmanAKoudstaalPJBretelerMMIncidence and prognosis of transient neurological attacksJAMA2007298242877288518159057
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in AdultsExecutive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA2001285192486249711368702
   PubMed Web of Science ®Google Scholar
• FreemanJVZhuRPOwensDKCost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillationAnn Intern Med2011154111121041570
   PubMed Web of Science ®Google Scholar
• AriesenMJClausSPRinkelGJAlgraARisk factors for intracerebral hemorrhage in the general population: a systematic reviewStroke20033482060206512843354
   PubMed Web of Science ®Google Scholar
• SorensenSVKansalARConnollySCost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspectiveThromb Haemost2011105590891921431243
   PubMed Web of Science ®Google Scholar
• HartRGBenaventeOMcBrideRPearceLAAntithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysisAnn Intern Med1999131749250110507957
   PubMed Web of Science ®Google Scholar
• EastonJDLopesRDBahitMCApixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trialLancet Neurol201211650351122572202
   PubMed Web of Science ®Google Scholar
  ErratumLancet Neurol201211121021
   Google Scholar
• HeronMHoyertDLMurphySLXuJKochanekKDTejada-VeraBDeaths: final data for 2006Natl Vital Stat Rep20095714113419788058
   PubMedGoogle Scholar
• MagnusonEAVilainKWangKCost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF-TIMI 48 trialAm Heart J201517061140115026678636
   PubMed Web of Science ®Google Scholar
• First DatabankFDB MedKnowledge: drug pricing Available from: http://www.fdbhealth.com/fdb-medknowledge-drug-pricingAccessed January 22, 2016
   Google Scholar
• Agency for Healthcare Research and QualityHealthcare Cost and Utilization Project (HCUP)2013 Available from: http://www.ahrq.gov/research/data/hcup/index.htmlAccessed January 2, 2016
   Google Scholar
• Academy of Managed Care Pharmacy (AMCP)The AMCP Format for Formulary Submissions: Version 3.1Alexandria (VA)AMCP2012 Available from: http://amcp.org/practice-resources/amcp-format-formulary-submisions.pdfAccessed January 2, 2016
   Google Scholar
• KrejczyMHarenbergJWehlingMObermannKLipGYCost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in GermanyBiomed Res Int2015201587692325853142
   PubMed Web of Science ®Google Scholar
• RognoniCMarchettiMQuagliniSLiberatoNLEdoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysisJ Thromb Thrombolysis201539214915424973057
   PubMed Web of Science ®Google Scholar
• MearnsEDolehYColemanCICost-effectiveness of high-dose edoxaban compared to adjusted-dose warfarin for prevention of stroke and systemic embolism in non-valvular atrial fibrillationPoster presented at: European Society for Cardiology Congress 2014August 30–September 3, 2014Barcelona, Spain
   Google Scholar
• MenschAStockSStollenwerkBMüllerDCost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillationPharmacoeconomics201533327128325404426
   PubMed Web of Science ®Google Scholar
• MoraisJAguiarCMcLeodEChatzitheofilouIFonseca SantosIPereiraSCost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese settingRev Port Cardiol201433953554425241380
   PubMedGoogle Scholar
• KrejczyMHarenbergJMarxSObermannKFrölichLWehlingMComparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countriesJ Thromb Thrombolysis201437450752324221805
   PubMed Web of Science ®Google Scholar
• RognoniCMarchettiMQuagliniSLiberatoNLApixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysisClin Drug Investig2014341917
   PubMed Web of Science ®Google Scholar
• KleintjensJLiXSimoensSCost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare settingPharmacoeconomics2013311090991824030788
   PubMed Web of Science ®Google Scholar
• HarringtonARArmstrongEPNolanPEJrMaloneDCCost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillationStroke20134461676168123549134
   PubMed Web of Science ®Google Scholar
• KansalARSharmaMBradley-KennedyCDabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada: comparative efficacy and cost-effectivenessThromb Haemost2012108467268222898892
   PubMed Web of Science ®Google Scholar
• LeeSAngladeMWPhamDPisacaneRKlugerJColemanCICost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillationAm J Cardiol2012110684585122651881
   PubMed Web of Science ®Google Scholar
• EdwardsSJHamiltonVNhereraLTrevorNBartonSRivaroxaban for the Prevention of Stroke and Systemic Embolism in People with Atrial Fibrillation: A Single Technology AppraisalLondonBMJ-TAG2011
   Google Scholar
• WellsGCoyleDCameronCTherapeutic Review: Safety, Effectiveness, and Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial FibrillationOttawaCanadian Collaborative for Drug Safety, Effectiveness and Network Meta-Analysis2012 Available at http://cadth.ca/media/pdf/NOAC_Therapeutic_Review_final_report.pdfAccessed January 2, 2016
   Google Scholar
• LanitisTCottéFEGaudinAFKachanerIKongnakornTDurand-ZaleskiIStroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirinJ Med Econ201417858759824831811
   PubMedGoogle Scholar
• ZhengYSorensenSVGonschiorAKComparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK settingClin Ther2014361220152028.e225438722
   PubMed Web of Science ®Google Scholar
• CoyleDCoyleKCameronCCost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillationValue Health201316449850623796283
   PubMed Web of Science ®Google Scholar
• CopeSClemensAHammèsFNoackHJansenJPCritical appraisal of network meta-analyses evaluating the efficacy and safety of new oral anticoagulants in atrial fibrillation stroke prevention trialsValue Health201518223424925773559
   PubMed Web of Science ®Google Scholar
• LipGYLarsenTBSkjøthFRasmussenLHIndirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillationJ Am Coll Cardiol201260873874622575324
   PubMed Web of Science ®Google Scholar
• CameronCCoyleDRichterTSystematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillationBMJ Open201446e004301
   PubMed Web of Science ®Google Scholar
• PinkJPirmohamedMHughesDAComparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillationClin Pharmacol Ther201394226927623619028
   PubMed Web of Science ®Google Scholar
• BakerWLPhungOJSystematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillationCirc Cardiovasc Qual Outcomes20125571171922912382
   PubMed Web of Science ®Google Scholar
• SchneeweissSGagneJJPatrickARChoudhryNKAvornJComparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillationCirc Cardiovasc Qual Outcomes20125448048622787066
   PubMed Web of Science ®Google Scholar
• RasmussenLHLarsenTBGraungaardTSkjøthFLipGYPrimary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysisBMJ2012345e709723129490
   PubMed Web of Science ®Google Scholar
• ManthaSAnsellJAn indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillationThromb Haemost2012108347648422740145
   PubMed Web of Science ®Google Scholar
• CanestaroWJPatrickARAvornJCost-effectiveness of oral anticoagulants for treatment of atrial fibrillationCirc Cardiovasc Qual Outcomes20136672473124221832
   PubMed Web of Science ®Google Scholar
• SullivanPWLawrenceWFGhushchyanVA national catalog of preference-based scores for chronic conditions in the United StatesMed Care200543773674915970790
   PubMed Web of Science ®Google Scholar
• SullivanPWSlejkoJFSculpherMJGhushchyanVCatalogue of EQ-5D scores for the United KingdomMed Decis Making201131680080421422468
   PubMed Web of Science ®Google Scholar
• EckmanMHRosandJGreenbergSMGageBFCost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillationAnn Intern Med20091502738319153410
   PubMed Web of Science ®Google Scholar
• VilainKRMagnusonEALiHCosts and cost-effectiveness of carotid stenting versus endarterectomy for patients at standard surgical risk: results from the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST)Stroke20124392408241622821614
   PubMed Web of Science ®Google Scholar
• YouJHNovel oral anticoagulants versus warfarin therapy at various levels of anticoagulation control in atrial fibrillation – a cost-effectiveness analysisJ Gen Intern Med201429343844624132628
   PubMed Web of Science ®Google Scholar